Literature DB >> 18563949

Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.

Stefan Vegter1, Cornelis Boersma, Mark Rozenbaum, Bob Wilffert, Gerjan Navis, Maarten J Postma.   

Abstract

The fields of pharmacogenetics and pharmacogenomics have become important practical tools to progress goals in medical and pharmaceutical research and development. As more screening tests are being developed, with some already used in clinical practice, consideration of cost-effectiveness implications is important. A systematic review was performed on the content of and adherence to pharmacoeconomic guidelines of recent pharmacoeconomic analyses performed in the field of pharmacogenetics and pharmacogenomics. Economic analyses of screening strategies for genetic variations, which were evidence-based and assumed to be associated with drug efficacy or safety, were included in the review. The 20 papers included cover a variety of healthcare issues, including screening tests on several cytochrome P450 (CYP) enzyme genes, thiopurine S-methyltransferase (TMPT) and angiotensin-converting enzyme (ACE) insertion deletion (ACE I/D) polymorphisms. Most economic analyses reported that genetic screening was cost effective and often even clearly dominated existing non-screening strategies. However, we found a lack of standardization regarding aspects such as the perspective of the analysis, factors included in the sensitivity analysis and the applied discount rates. In particular, an important limitation of several studies related to the failure to provide a sufficient evidence-based rationale for an association between genotype and phenotype. Future economic analyses should be conducted utilizing correct methods, with adherence to guidelines and including extensive sensitivity analyses. Most importantly, genetic screening strategies should be based on good evidence-based rationales. For these goals, we provide a list of recommendations for good pharmacoeconomic practice deemed useful in the fields of pharmacogenetics and pharmacogenomics, regardless of country and origin of the economic analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18563949     DOI: 10.2165/00019053-200826070-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  59 in total

1.  Nature, nurture and human disease.

Authors:  Aravinda Chakravarti; Peter Little
Journal:  Nature       Date:  2003-01-23       Impact factor: 49.962

Review 2.  The role of cost-effectiveness analysis in the era of pharmacogenomics.

Authors:  Christopher R Flowers; David Veenstra
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model.

Authors:  Roy H Perlis; David A Ganz; Jerry Avorn; Sebastian Schneeweiss; Robert J Glynn; Jordan W Smoller; Philip S Wang
Journal:  J Clin Psychopharmacol       Date:  2005-10       Impact factor: 3.153

Review 4.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

Authors:  W H Chou; F X Yan; J de Leon; J Barnhill; T Rogers; M Cronin; M Pho; V Xiao; T B Ryder; W W Liu; C Teiling; P J Wedlund
Journal:  J Clin Psychopharmacol       Date:  2000-04       Impact factor: 3.153

6.  Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

Authors:  Dyfrig A Hughes; F Javier Vilar; Charlotte C Ward; Ana Alfirevic; B Kevin Park; Munir Pirmohamed
Journal:  Pharmacogenetics       Date:  2004-06

7.  Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.

Authors:  J Winter; A Walker; D Shapiro; D Gaffney; R J Spooner; P R Mills
Journal:  Aliment Pharmacol Ther       Date:  2004-09-15       Impact factor: 8.171

8.  Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor.

Authors:  Madlaina Costa-Scharplatz; Antoinette D I van Asselt; Lucas M Bachmann; Alfons G H Kessels; Johan L Severens
Journal:  Pharmacogenet Genomics       Date:  2007-05       Impact factor: 2.089

Review 9.  Translating pharmacogenomics: challenges on the road to the clinic.

Authors:  Jesse J Swen; Tom W Huizinga; Hans Gelderblom; Elisabeth G E de Vries; Willem J J Assendelft; Julia Kirchheiner; Henk-Jan Guchelaar
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069

10.  What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors?--Protocol of a systematic review.

Authors:  M Scharplatz; M A Puhan; J Steurer; L M Bachmann
Journal:  BMC Med Genet       Date:  2004-09-10       Impact factor: 2.103

View more
  25 in total

Review 1.  Cost effectiveness of pharmacogenomics: a critical and systematic review.

Authors:  William B Wong; Josh J Carlson; Rahber Thariani; David L Veenstra
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  Challenges of translating genetic tests into clinical and public health practice.

Authors:  Wolf H Rogowski; Scott D Grosse; Muin J Khoury
Journal:  Nat Rev Genet       Date:  2009-07       Impact factor: 53.242

3.  Genetic testing in the European Union: does economic evaluation matter?

Authors:  Fernando Antoñanzas; R Rodríguez-Ibeas; M F Hutter; R Lorente; C Juárez; M Pinillos
Journal:  Eur J Health Econ       Date:  2011-05-20

4.  A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events.

Authors:  M E Moretti; D F Lato; H Berger; G Koren; S Ito; W J Ungar
Journal:  Pharmacogenomics J       Date:  2017-07-11       Impact factor: 3.550

5.  A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders.

Authors:  Francis X Brennan; Kathryn R Gardner; Jay Lombard; Roy H Perlis; Maurizio Fava; Herbert W Harris; Rachel Scott
Journal:  Prim Care Companion CNS Disord       Date:  2015-04-16

Review 6.  The economic considerations and implications of the stratification of future oncology therapeutics.

Authors:  Maria Gazouli; Kyriakos Souliotis
Journal:  Mol Diagn Ther       Date:  2014-08       Impact factor: 4.074

7.  Key emerging themes for assessing the cost-effectiveness of reporting incidental findings.

Authors:  Kathryn A Phillips; Uri Ladabaum; Mark J Pletcher; Deborah A Marshall; Michael P Douglas
Journal:  Genet Med       Date:  2015-04       Impact factor: 8.822

Review 8.  Is individualized medicine more cost-effective? A systematic review.

Authors:  Maximilian H M Hatz; Katharina Schremser; Wolf H Rogowski
Journal:  Pharmacoeconomics       Date:  2014-05       Impact factor: 4.981

9.  The economic value of personalized medicine tests: what we know and what we need to know.

Authors:  Kathryn A Phillips; Julie Ann Sakowski; Julia Trosman; Michael P Douglas; Su-Ying Liang; Peter Neumann
Journal:  Genet Med       Date:  2013-10-17       Impact factor: 8.822

10.  Concepts of 'personalization' in personalized medicine: implications for economic evaluation.

Authors:  Wolf Rogowski; Katherine Payne; Petra Schnell-Inderst; Andrea Manca; Ursula Rochau; Beate Jahn; Oguzhan Alagoz; Reiner Leidl; Uwe Siebert
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.